Global MedTech mergers and acquisitions (M&A) nearly doubled from 2023 to 2024. While dealmaking focuses on innovation and growth, regulatory affairs (RA) remain the cornerstone of sustainable value creation.
This whitepaper by Syrma Johari MedTech examines how regulatory integration influences MedTech M&A outcomes. Early, structured RA frameworks mitigate compliance risks, preserve market access, and accelerate post-merger commercialization. Companies neglecting RA may face loss of certifications, delayed approvals, or reputational damage.
The paper provides a comprehensive framework for embedding Quality Assurance and Regulatory Affairs (QARA) across all phases of the MedTech M&A lifecycle: pre-transaction due diligence, deal structuring, integration, and cross-border alignment. It outlines practical strategies including:
With the global regulatory affairs outsourcing market expected to reach USD 13.8 billion by 2030, specialized RA partners are vital to seamless M&A execution.
Syrma Johari MedTech enables OEMs to gain lasting competitive advantage in today’s high-stakes M&A landscape. Our quality and regulatory experts help MedTech companies integrate regulatory systems and ensure compliance continuity through every phase of M&A.
AI-Powered Assistant
